EUCTR2010-022091-31-IT进行中（未招募）不适用
Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study. - GOIM 2802
GOIM GRUPPO ONCOLOGICO MERIDIONALE0 个研究点开始时间: 2011年6月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Histologically proven diagnosis of colorectal cancer -Mutation Status KRAS -No previous first line chemoterapy treatment - Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-More than one line of treatment -Presence of brain metastases -
- •Patients with uncontrolled diseases(cardiac disease)
研究者
相似试验
进行中（未招募）
不适用
Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment lineEUCTR2014-004436-19-ITG.O.N.O.
进行中（未招募）
不适用
Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer - NDEUCTR2006-001779-39-ITAzienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
已完成
不适用
FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility studyColorectal cancerJPRN-UMIN000003673niversity of Toyama20
已完成
2 期
Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.JPRN-UMIN000002378Japan South West Oncology Group45
进行中（未招募）
3 期
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal CancerColorectal CancerNCT04230187Yanhong Deng528